Harrow, a biopharmaceutical company specializing in ophthalmology, recently unveiled its impressive financial results for the fourth quarter and the entirety of 2025. These figures demonstrate a period of substantial expansion and strategic realignment, positioning the company for continued growth in the coming year. Executives detailed plans for significant commercial investments, the introduction of new therapeutic products, and ongoing clinical research to bolster its key offerings.
Harrow Unveils Strong Financials and Ambitious 2026 Growth Strategy
In a recent announcement, ophthalmic biopharmaceutical leader Harrow disclosed a period of significant achievement and strategic planning. On Tuesday, March 3, 2026, during the company's fourth-quarter earnings call, CEO Mark Baum highlighted Harrow's five-year transformation into a diverse ophthalmic platform. President and CFO Andrew Boll reported robust financial results for Q4 2025, with consolidated revenue reaching $89.1 million, marking a 33% year-over-year increase. The full fiscal year 2025 saw revenue climb to $272 million, a 36% rise from 2024, while adjusted EBITDA for the year totaled $61.9 million, growing by 54%.
Looking ahead to 2026, Harrow projects full-year revenue between $350 million and $365 million, with adjusted EBITDA estimated to be between $80 million and $100 million. The company anticipates stronger performance in the latter half of the year due to seasonal market dynamics. Key growth drivers like VEVYE, IHEEZO, and TRIESENCE showed accelerated performance in Q4 2025. VEVYE's revenue reached $25.9 million in Q4 and $88.7 million for the full year, a remarkable 216% increase. IHEEZO generated $35.9 million in Q4 and $81.3 million for the full year, demonstrating 65% year-over-year growth. TRIESENCE, separately reported for the first time, posted $5.1 million in Q4 and $9.9 million for the full year, a 193% increase.
Harrow plans to significantly increase its commercial investment in 2026, with selling, general, and administrative expenses (SG&A) projected to be between $185 million and $205 million. This includes the addition of approximately 100 new sales roles in the first half of the year to support product launches and market expansion. The company is preparing for the launch of BYQLOVI in Q2 and BYOOVIZ in mid-2026. Chief Scientific Officer Amir Shojaei confirmed that the company is on track for an NDA submission for its opioid-free sedation candidate, G-MELT, in early 2027. Additionally, studies are underway to gather procedure-specific evidence for IHEEZO, with data expected at ASRS in July and from a 240-patient Phase IV trial by the end of 2026. Although IHEEZO is set to lose pass-through status on April 1, management is confident in its strategic shifts and potential pricing improvements starting Q3 2026.
Harrow's strong financial foundation, including $72.9 million in cash and cash equivalents by the end of 2025, underpins these ambitious initiatives. The company's focus on innovative ophthalmic therapies and strategic market expansion positions it for continued leadership in the biopharmaceutical sector.
The strategic maneuvers outlined by Harrow's leadership highlight a proactive approach to navigating market complexities and capitalizing on opportunities within the ophthalmic sector. Their emphasis on increased commercial investment and a robust product pipeline suggests a strong belief in their long-term growth trajectory. This forward-thinking strategy, coupled with solid financial performance, offers a compelling narrative for investors and stakeholders in the evolving healthcare landscape.